Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
Dr. Jeffrey Mechanick Part 8, Joint A1C Recommendations
HOMERUN SLIDES — Great Clinical Presentation Highlights
EMPA-REG Outcome Trial, Part 2
CLINICAL GEMS — The Best from Diabetes Texts
MOST POPULAR ARTICLES OF THE MONTH
#1 Towards a Game-Changing Type 1 Diabetes Vaccine
#2 FDA Approves 2 New Diabetes Combos
#3 Implantable CGMS Submitted to FDA
0
Editor's Note
Happy Holidays from all of us here at Diabetes In Control.
Dr. Jeffrey Mechanick, from the Icahn School of Medicine at Mount Sinai, NY, was chosen president of the American College of Endocrinology this past year and played a big role in new Joint A1c recommendations. He has been chatting with our publisher, Steve Freed, and sharing his take on these new guidelines. This week he shares an insightful view of the comprehensive focus of these new guidelines.
Dave Joffe
Editor-in-chief
0
DISASTERS AVERTED — Near Miss Case Studies
Female, 20 years of age, type 2 diabetes, is obese with anxiety disorder, untoward response to several classes of agents. Reports eating lower carbs since last seen. During the warm weather, random glucose levels and A1C were near normal. Today is a cold winter day. Random glucose 188mg/dl.
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 8 of this Exclusive Interview, Dr. Mechanick explains the comprehensive focus of the AACE A1C guidelines.
HOMERUN SLIDES — Great Clinical Presentation Highlights
In this week’s Homerun Slides, EMPA-REG Outcome, examining the long-term effects of empagliflozin versus using a placebo on the heart and mortality risk in patients with type 2.
CLINICAL GEMS — The Best from Diabetes Texts
Similar to GLP-1, GIP acts through specific receptors belonging to the seven transmembrane-domain family of receptors. These receptors are expressed in the endocrine pancreas, on adipocytes, and in the brain
MOST POPULAR ARTICLES OF THE MONTH
In part 3 of this exclusive interview, Dr. Faustman discusses how a cure based on the inexpensive BCG vaccine could permanently change type 1 treatment, and whether results could also apply to type 2.
IDegLira, LixiLan go head-to-head; FDA approves Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day.
Premarket Approval application submitted for Eversense® CGM system.